NeuroRx Inc, a clinical stage, small molecule pharmaceutical company, and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF), a Swiss-based publicly-traded drug development company, have received US Food and Drug Administration (FDA) Investigational New Drug (IND) approval to test RLF-100 (aviptadil) for inhaled use in the treatment of patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure, it is reported on Thursday.
The first phase is to start with patients hospitalised for severe COVID-19 who do not yet have respiratory failure. If promising results are revealed then the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the requirement for hospital admission.
The clinical trial of the product's inhaled formulation is likely to commence on or before 1 September 2020.
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon